Extended regimens of the vaginal contraceptive ring: cycle control

Contraception

Volumn 80, Issue 5, 2009, Pages 430-435

  Guazzelli, Cristina Aparecida Falbo ^a   Barreiros, Fernando Augusto ^a,b   Barbosa, Ricardo ^b   Araújo, Fábio Fernando de ^a   Moron, Antonio Fernandes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PAULISTA UNIVERSITY   (Brazil)

Author keywords

Etonogestrel; Extended regimens; Hormonal contraceptive; Vaginal contraceptive ring

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; ETONOGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NAUSEA; NORMAL HUMAN; ORAL CONTRACEPTION; PROSPECTIVE STUDY; RISK REDUCTION; SPOTTING; STOMACH PAIN; VAGINA CONTRACEPTION; VAGINA RING; VOMITING;

ADOLESCENT; ADULT; CONTRACEPTION; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; YOUNG ADULT;

EID: 70349895326     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.05.004     Document Type: Article

References (15)

1. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
2. FDA approves NuvaRing contraceptive implant. J Gend Specif Med 5 (2002) 6
3. Roumen F., Apter D., Mulders T., and Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16 (2001) 469-475
4. Dieben T.O., Roumen F.J., and Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 100 (2002) 585-593
5. Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care Suppl 2 (2002) 19-24
6. Oddsson K., Leifels-Fischer B., Wiel-Masson D., et al. Superior cycle control with a contraceptive vaginal ring compared with a an oral contraceptive containing 30 mcg ehtinylestradiol and 150 mcg levonorgestrel: a randomized trial. Hum Reprod 20 (2005) 557-562
7. Kwiecien M., Edelman A., Nichols M.D., and Jensen J.T. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a lowdose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
8. Edelman A. Menstrual nirvana: amenorrhea through the use of continuous oral contraceptives. Curr Womens Health Rep 6 (2002) 434-438
9. Vree M. Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care Suppl 2 (2002) 25-30
10. Miller L., Verhoeven C., and Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol 3 (2005) 473-482
11. World Health Organization. Medical eligibility criteria for contraceptive use. Reproductive Health and Research. 3rd ed (2004), WHO, Geneva
12. Mishell D., Guillebaud J.M., Westhoff C.L., et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 75 (2006) 4-10
13. Mishell Jr. D.R., Guillebaud J., Westhoff C.L., et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 75 1 (2007) 11-15
14. Altman D. Practical Statistics for medical research (1991), Chapman and Hall, London 250
15. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72, 93.